Company: SMNR
Filing Date: 2025-06-11
Form Type: S-4/A
Source: 0001193125-25-139124
Chunk: 749

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: S-4/A
Chunk 749
---
 EPS purpose, the warrants and notes are anti-dilutive since they would generally not be reflected in basic or diluted EPS until the contingency is resolved. For

<div align='center'>F-23</div>

the years ended December 31, 2024 and 2023, the Company did not have any other dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted income per ordinary share is the same as basic earnings per ordinary share for the periods presented.

The net income per share presented in the consolidated statements of operations is based on the following:

|                                                   |     | For the yearended 
 December 31,      
 2024              |            |   |     | For the yearendedDecember 31,2023 |            |   |
|:--------------------------------------------------|:----|:------------------|:-----------|:--|:----|:----------------------------------|-----------:|:--|
| Net (loss)/income                                 |     | $                 | (167,306   | ) |     | $                                 |    632,536 |   |
| Accretion of temporary equity to redemption value |     |                   | (1,968,370 | ) |     |                                   | (5,643,271 | ) |
| Net loss including accretion of temporary equity  |     | $                 | (2,135,676 | ) |     | $                                 | (5,010,735 | ) |

|                                                                |     | For theYear EndedDecember 31, 2024 |            |   |     |                      |            |   |     | For theYear EndedDecember 31, 2023 |            |   |     |                           |            |   |
|:---------------------------------------------------------------|:----|:-----------------------------------|-----------:|:--|:----|:---------------------|-----------:|:--|:----|:-----------------------------------|-----------:|:--|:----|:--------------------------|-----------:|:--|
|                                                                |     | RedeemableCommonStock              |            |   |     | Non-RedeemableCommon 
 Stock                |            |   |     | RedeemableCommonStock              |            |   |     | Non-RedeemableCommonStock |            |   |
| Basic and diluted net income (loss) per share:                 |     |                                    |            |